Empagliflozin reduced the expression of SREBP1 in another preclinical study in a rat model with no obesity or hyperglycemia, which suggested possible benefits in clinical practice in pre-diabetes and pre-obesity states [81]. Here, SREBF1 is linked to obesity disorder.